Clara De Risi
University of Bari
5 Papers
Clara De Risi is an academic researcher from University of Bari. The author has contributed to research in topics: Palonosetron & Netupitant. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Francesco Gaudio,Annamaria Giordano,Tommasina Perrone,Domenico Pastore,Paola Curci,Mario Delia,Anna Napoli,Clara De Risi,Alessandro Spina,Rosalia Ricco,Vincenzo Liso,Giorgina Specchia +11 more
TL;DR: The data show that a high Ki67 expression and bulky disease could represent possible predictive factors of poor prognosis, which would help to identify a high-risk subgroup of newly diagnosed DLBCL.
62
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Nicola Di Renzo,Maurizio Musso,Rosanna Scimè,Alessandra Cupri,Tommasina Perrone,Clara De Risi,Domenico Pastore,Attilio Guarini,Andrea Mengarelli,Fabio Benedetti,Patrizio Mazza,Vera Capria,P Chiusolo,Luca Cupelli,Vincenzo Federico,Valentina Bozzoli,Anna Rita Messa,Paolo Codega,Erminio Bonizzoni,Giorgina Specchia +19 more
TL;DR: This study demonstrated that multiple alternate dosing of NEPA without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting, with a good tolerability profile.
Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Nicola Di Renzo,Maurizio Musso,Rosanna Scimè,Alessandra Cupri,Tommasina Perrone,Clara De Risi,Domenico Pastore,Attilio Guarini,Andrea Mengarelli,Fabio Benedetti,Patrizio Mazza,Saveria Capria,P Chiusolo,Luca Cupelli,Vincenzo Federico,Valentina Bozzoli,Anna Rita Messa,Rosella Matera,Davide Seripa,Paolo Codega,Erminio Bonizzoni,Giorgina Specchia +21 more
TL;DR: The authors evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin's lymphoma.
Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real life experience of rete ematologica pugliese (rep)
Anna Mele,E. Prete,Clara De Risi,Stefania Citiso,Giuseppina Greco,Antonietta Falcone,Grazia Sanpaolo,Giuseppe Mele,Angela Giannotta,Carolina Vergine,Giovanni Reddiconto,Giulia Palazzo,Sabrina Sabatelli,Candida Germano,R. Miccolis,Paola Curci,Gaetano Palumbo,Massimo Offidani,Rita Rizzi,Nicola Cascavilla,Domenico Pastore,Nicola Di Renzo,Patrizio Mazza,Giuseppe Tarantini,Attilio Guarini,Silvana Capalbo,Giorgina Specchia,Antonino Greco,Rosa De Francesco,Silvia Sibilla,Lorenzo Tonialini,Maria Rosaria Morciano,Vincenzo Pavone +32 more
TL;DR: KRd should be used as bridge regimen to ASCT with remarkable improvement in response and PFS rates, and Elderly patients have tolerated therapy very well, without additional side effects compared to younger patients, except for cardiac impairment.
Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.
Francesco Gaudio,Annamaria Giordano,Vincenzo Pavone,Tommasina Perrone,Paola Curci,Domenico Pastore,Mario Delia,Clara De Risi,Alessandro Spina,Vincenzo Liso,Giorgina Specchia +10 more
TL;DR: Therapy regimens for very late relapse HL are warranted to minimize complications.